

Mark Yarchoan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9288723/publications.pdf>

Version: 2024-02-01

67
papers

6,815
citations

182225

30
h-index

129628

63
g-index

71
all docs

71
docs citations

71
times ranked

12915
citing authors

#	ARTICLE	IF	CITATIONS
1	Calciophylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge. <i>Cureus</i> , 2022, 14, e21478.	0.2	1
2	Galectin-9 expression and decreased survival in advanced biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 465-465.	0.8	0
3	Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials. <i>Gastrointestinal Tumors</i> , 2022, 9, 19-26.	0.3	4
4	Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	25
5	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. <i>JCO Precision Oncology</i> , 2022, , .	1.5	19
6	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4336-4345.	3.2	3
7	Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. <i>Cancer Control</i> , 2021, 28, 107327482110099.	0.7	4
8	Tumor and Systemic Immunomodulatory Effects of MEK Inhibition. <i>Current Oncology Reports</i> , 2021, 23, 23.	1.8	6
9	Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1374-1375.	1.4	1
10	Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. <i>Genome Biology</i> , 2021, 22, 154.	3.8	30
11	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. <i>JCI Insight</i> , 2021, 6, .	2.3	10
12	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 891-903.	5.7	147
13	Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. <i>Cancer Immunology Research</i> , 2021, 9, 1187-1201.	1.6	11
14	Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
15	Systemic inhibition of PTPN22 augments anticancer immunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	24
16	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>OncoImmunology</i> , 2021, 10, 2001159.	2.1	10
17	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	56
18	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 545-551.	3.2	100

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 1485-1494.	1.3	48
20	Response to Crizotinib in <i>ROS1</i> Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 825-828.	1.5	7
21	Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case report. <i>BMC Pulmonary Medicine</i> , 2020, 20, 298.	0.8	2
22	Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. , 2020, 8, e000932.		16
23	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
24	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	1.3	143
25	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. , 2020, 8, e000394.		39
26	Abstract CT043: A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study. <i>Cancer Research</i> , 2020, 80, CT043-CT043.	0.4	11
27	Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. <i>JCI Insight</i> , 2020, 5, .	2.3	17
28	Effects of B cell-activating factor on tumor immunity. <i>JCI Insight</i> , 2020, 5, .	2.3	27
29	Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development. <i>JCI Insight</i> , 2020, 5, .	2.3	20
30	Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. <i>Npj Systems Biology and Applications</i> , 2019, 5, 29.	1.4	17
31	MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. <i>PLoS ONE</i> , 2019, 14, e0224600.	1.1	23
32	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
33	Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy. <i>JAMA Oncology</i> , 2019, 5, 1497.	3.4	5
34	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
35	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. <i>Cancer Immunology Research</i> , 2019, 7, 886-895.	1.6	171
36	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 805-812.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
38	Successful Treatment of Neoplastic Fever with Oxybutynin. <i>Journal of Palliative Medicine</i> , 2019, 22, 1491-1491.	0.6	0
39	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	345
40	Successful Treatment of Scar Pain with Scrambler Therapy. <i>Cureus</i> , 2019, 11, e5903.	0.2	4
41	Prophylactic Vaccines for Nonviral Cancers. <i>Annual Review of Cancer Biology</i> , 2018, 2, 195-211.	2.3	8
42	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	206
43	Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. , 2018, 6, 84.		83
44	Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	120
45	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
46	Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 699-706.	1.2	35
47	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1402-1407.	2.9	54
48	Strategies for Increasing Pancreatic Tumor Immunogenicity. <i>Clinical Cancer Research</i> , 2017, 23, 1656-1669.	3.2	131
49	Ipilimumab-Induced Enteritis without Colitis: A New Challenge. <i>Case Reports in Oncology</i> , 2017, 9, 705-713.	0.3	41
50	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 7333-7339.	3.2	128
51	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	3.2	115
52	Tumor Mutational Burden and Response Rate to PD-1 Inhibition. <i>New England Journal of Medicine</i> , 2017, 377, 2500-2501.	13.9	2,321
53	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44073-44081.	0.8	63
54	Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 114268-114280.	0.8	169

#	ARTICLE	IF	CITATIONS
55	pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. <i>Hormones and Cancer</i> , 2016, 7, 188-195.	4.9	11
56	Reply to C. Bal et al and M. Xing. <i>Journal of Clinical Oncology</i> , 2015, 33, 2483-2483.	0.8	0
57	A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6072-6072.	0.8	12
58	Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. <i>Neurobiology of Aging</i> , 2014, 35, 793-801.	1.5	114
59	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. <i>Acta Neuropathologica</i> , 2014, 128, 679-689.	3.9	158
60	Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease. <i>Diabetes</i> , 2014, 63, 2253-2261.	0.3	196
61	Molecular predictors of response to sorafenib in patients with radioactive iodine-resistant advanced thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6088-6088.	0.8	3
62	Phase II trial of sorafenib in advanced thyroid cancer: A disease site analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17000-e17000.	0.8	2
63	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2013, 333, 9-12.	0.3	55
64	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. <i>Brain</i> , 2012, 135, 3749-3756.	3.7	228
65	Duplex ultrasound imaging to detect limb stenosis or kinking of endovascular device. <i>Journal of Vascular Surgery</i> , 2012, 55, 1577-1580.	0.6	17
66	Chronic Losartan Administration Reduces Mortality and Preserves Cardiac but Not Skeletal Muscle Function in Dystrophic Mice. <i>PLoS ONE</i> , 2011, 6, e20856.	1.1	53
67	Who Will Manage American Patients With Diabetes? Residents' Career Preferences and Perceptions of Diabetes Care. <i>Endocrine Practice</i> , 2011, 17, 235-239.	1.1	3